APA (7th ed.) Citation

Karadurmus, N., Sendur, M. A. N., Karaca, B., Olmez, O. F., Hacibekiroglu, I., Coskun, H. S., . . . Abali, H. (2018). Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Galenos Publishing House.

Chicago Style (17th ed.) Citation

Karadurmus, Nuri, et al. Experience from Turkish Centers Participating in the Early Access Program (EAP): Preliminary Real-world Safety Data of Nivolumab (nivo) Combined with Ipilimumab (ipi) in Pre-treated Advanced Melanoma Patients. Galenos Publishing House, 2018.

MLA (9th ed.) Citation

Karadurmus, Nuri, et al. Experience from Turkish Centers Participating in the Early Access Program (EAP): Preliminary Real-world Safety Data of Nivolumab (nivo) Combined with Ipilimumab (ipi) in Pre-treated Advanced Melanoma Patients. Galenos Publishing House, 2018.